期刊文献+

超滤-HPLC法测定盐酸拓扑替康脂质体包封率 被引量:15

Determination of entrapment efficiency of topotecan liposomes by ultrafiltration-HPLC
下载PDF
导出
摘要 目的:对盐酸拓扑替康脂质体进行质量评价,测定盐酸拓扑替康脂质体的包封率。方法:采用超滤法分离脂质体与游离药物;采用HPLC测定药物含量,计算包封率。结果:超滤法能很好地将脂质体与游离药物分离,游离药物的平均回收率在96.9%~102.3%之间,超滤加样回收率在96.7%~101.6%之间,脂质体不能透过截留相对分子质量为50000的超滤膜。在所选色谱条件下,盐酸拓扑替康得到良好分离,辅料不干扰测定,盐酸拓扑替康在1.0~40.0mg·L^-1内线性关系良好(r=0.9998),日内和日间RSD均〈3.0%(n=5),加样回收率在98.5%~100.3%之间,RSD为1.4%。用此方法测定3份盐酸拓朴替康脂质体的包封率为92.41%~95.14%,RSD在1.26%~2.03%。结论:该方法可用于盐酸拓扑替康脂质体包封率的测定。 Objective:To determine the entrapment efficiency of topotecan hydrochloride liposomes. Methods:An ultrafihration was employed to separate the free drug from the liposomes. The content of topotecan hydrochloride was quantified by HPLC consisted of a Kromasil C,s column, a mobile phase of water-acetonitrile-trifluoroacetic acid (85 : 20:0.1 ) with a flow rate of 0.8 mL· min^-1 and UV detection wavelength at 228 nm. Results: The free topotecan hydrochloride was well separated from the liposomes using uhrafihration membrane that blocks the penetration of a compound with molecular weight of 50 000 or above. The recovery rate of topotecan hydrochloride by uhrafihration and free topotecan was in a range of 96.7% - 101.6% and 96.9% - 102.3% , respectively. A calibrated linear curve of topotecan concentration was within 1.0 -40.0mg·L^-1( r = 0. 999 8 ) , and RSD within day and between days was all less than 3.0% ( n = 5) , the recovery rate of topotecan with blank liposomes was in a range of 98.5% - 100.3% with RSD of 1.4% or below. The entrapment efficiency of three batches of topotecan hydrochloride liposomes was in a range of 92.41% - 95.14% ,with RSD of 1.26% -2.03% by uhrafiltration-HPLC. Conclusion : The ultrafiltration-HPLC method may be used for the determination of entrapment efficiency of topotecan hydrochloride liposomes.
出处 《中国新药杂志》 CAS CSCD 北大核心 2007年第1期58-61,共4页 Chinese Journal of New Drugs
基金 国家自然科学基金(39570843)
关键词 超滤法 高效液相色谱法 盐酸拓扑替康 脂质体 包封率 ultrafihration high performance liquid chromatography ( HPLC ) topotecan hydro- chloride liposomes entrapment efficiency
  • 相关文献

参考文献8

  • 1张秀国,雍政,张谦,赵水明.拓扑替康在临床应用的研究进展[J].中国新药与临床杂志,2003,22(11):691-696. 被引量:6
  • 2FASSBERG J,STELLA VJ.A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues[J].J Pharm Sci,1992,81 (7):676-684.
  • 3郝艳丽,邓英杰,陈妍,王秀敏.盐酸拓扑替康脂质体的制备及影响因素考察[J].中国药学杂志,2004,39(8):602-604. 被引量:7
  • 4LIU JJ,HONG RL,CHENG WF,et al.Simple and efficient liposomal encapsulation of topotecan by ammonium sulfate gradient:stability,pharmacokinetic and therapeutic evaluation[J].Anticancer Drugs,2002,13(7):709 -717.
  • 5ABRAHAM SA,EDWARDS K,KARLSSON G,et al.An evaluation of transmembrane ion gradient-mediated encapsulation of topotecan within liposomes[J].J Controlled Release,2004,96(3):449 -461.
  • 6GREGORIADIS G.Liposome Technology Volume I,Liposome Preparation and Related Techniques[M].Second edition.London,England:CRC press,1993:585-586.
  • 7戴建国,赵俊,赵小伟.注射用盐酸拓扑替康的质量分析方法研究[J].中国新药杂志,2003,12(8):638-640. 被引量:5
  • 8ALBERT SK,KAMLESH P,NAGESH RP,et al.Preformulation studies to aid in the development of a ready-to-use injectable solution of the antitumor agent,topotecan[J].Int J Pharm,1996,127(2):229 -237.

二级参考文献33

  • 1Brogden RN, Wiseman LR. Topotecan: a review of potential in advanced ovarian cancer[J] .Drugs, 1998,56(4):709-723.
  • 2Kingsbury WD, Boehm J C,Jakas DR, et al. Sythesis of water-soluble (Aminoalkyl) camptothecin analogues: inhibition of topoisomerase I and antitumor aetivity[J]. J Med Chem, 1991,34 (1):98-107.
  • 3Lackey K, Stembach DD, Croom DK, et al. Water soluble inhibitors of topoisomerase I: quaternary salt derivatives of camp-tothecin[J] .J Meal Chem, 1996,39(3):713-719.
  • 4WALL JG, BENEDETTI JK, O'RROUIKE MA, et al. Phase II trial to in hepatocellular carcinoma: a southwest oncology group study[J]. Invest New Drugs, 1997,15(3) :257-260.
  • 5BROWN ZA, BENEDETTI JK, WATTS DH, et al. Phase II trial to topotecan in hepatocellular carcinoma: a southwest oncology group study[J ]. Invest New Drugs, 1997,15(3):257-260.
  • 6KANCHERLA RR, NAIR JS, AHMED T, et al. Evaluation of topotecan and etoposide for Non-Hodgkin Lymphoma[ J ]. Cancer, 2001, 91(3) : 463-471.
  • 7MUDERSPACH LI, BLESSING JA, LEVENBACK C, et al. A phase Ⅱ study of Topotecan in patients with squamous cell carcinoma of the cervix: a gynecologic oncology group study[J]. Gynecol oncol, 2000, 81(2):213-215.
  • 8ARDIZZONI A, HANSEN H, DOMBERNOWSKY P, et al.Topotecan,a new active drug in the second-line treatment of small-cell lung cancer: a phase lI study in patients with refractory and sensitive diease[J]. J Clin Oncol,1997,15(5) :2090-2096.
  • 9SCHILLER JH, KIM KM, HUTSON P, et al. Phase Ⅱ study to topotecan in patients with extensive stage small cell carcinoma of the lung: an eastern cooperative oncolgy group trail[J]. J Clin Oncol, 1996,14 (8) : 2345-2352.
  • 10von PAWEL J ,SCHILLER JH, SHEPFERD FA, et al. Topotecan versus cyclophosphmide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer[J]. J Clin Oncol,1999,17(2) : 658-667.

共引文献14

同被引文献118

引证文献15

二级引证文献146

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部